Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Tissue-repair peptides — BPC-157 and TB-500 — used for rehab, gut and joint healing. Most evidence is preclinical; the human data is thinner than enthusiasts admit.
Recovery peptides are the category where the gap between bodybuilder enthusiasm and peer-reviewed evidence is widest. Two compounds dominate the conversation — BPC-157 and TB-500 — and both have interesting preclinical mechanism stories built on years of animal model work. The human randomized-trial dataset, by contrast, is one or two small studies of marginal methodological quality. Neither compound is FDA-approved. Both sit on a tightening regulatory track. This page is the honest read on what the evidence actually supports.
Neither BPC-157 nor TB-500 is FDA-approved. There is no branded recovery-indication peptide on the US market. The compounds reach patients exclusively through compounding pharmacies, research-chemical suppliers, or — depending on the source — the gray market.
The compounding pathway is what most legitimate telehealth platforms use. Under Section 503A, a licensed compounding pharmacy can prepare a non-approved drug for a specific patient on a specific physician's prescription, provided the active ingredient meets one of three eligibility criteria (USP monograph, component of an FDA-approved drug, or appearance on the FDA's 503A bulks list). The regulatory architecture is detailed in our compounded vs branded peptides explainer.
For BPC-157 specifically, the regulatory ground has shifted in the past two years. The FDA placed BPC-157 on Category 2 of the 503A bulks list interim evaluation — a designation indicating that the agency identified significant safety risks and considers the substance not eligible for compounding under 503A pending further review [10]. That placement does not, by itself, ban compounding; the bulk substance can still be sourced in principle under USP monograph or approved-drug-component routes (BPC-157 has neither, which is the practical problem). What it does is flag the category for ongoing enforcement attention.
BPC-157 is a synthetic 15-amino-acid sequence corresponding to a partial sequence of a larger "Body Protection Compound" originally identified in gastric juice. It was characterized and named by Predrag Sikiric's group at the University of Zagreb beginning in the 1990s. The literature on BPC-157 is unusual in two ways. First, it is voluminous — the 2025 Pharmaceuticals literature and patent review [1] and the 2019 Cell and Tissue Research review of musculoskeletal soft tissue applications [2] each cite dozens of preclinical papers. Second, the vast majority of that literature is preclinical — rat and mouse models of wound healing, tendon repair, GI ulcer protection, and angiogenesis.
The 2025 HSS Journal systematic review focused specifically on BPC-157 in orthopaedic sports medicine and synthesized the human evidence such as it is — predominantly case series and preclinical extrapolation [3]. A 2021 Frontiers in Pharmacology review covered the wound-healing literature in detail [4]. The 2025 Current Reviews in Musculoskeletal Medicine narrative review took the deliberately even-handed title "Regeneration or Risk?" and is the cleanest editorial-tone summary of the field [5].
The one human study most often cited is a 2021 paper in Alternative Therapies in Health and Medicine reporting on intra-articular BPC-157 for knee pain [6]. We treat it as Tier B evidence. The journal is not high-impact, the design was open-label without proper controls, and the sample size was small. It is not the kind of trial that establishes efficacy at FDA-approval scale; it is the kind of trial that motivates a properly-controlled phase 2 trial that has not yet been done.
What is not in the human literature: a well-powered, placebo-controlled, randomized trial of BPC-157 for any specific musculoskeletal indication in humans. Until that exists, the strongest editorial position is the one the 2025 HSS systematic review takes — interesting mechanism, preclinical signal worth pursuing, current human evidence not sufficient to support routine clinical use.
TB-500 is a synthetic fragment of Thymosin Beta-4 (TB-4), a 43-amino-acid protein found in nearly all human tissues. The synthetic fragment is shorter (typically 17 amino acids) and represents only part of the full TB-4 sequence. The marketing framing — "TB-500 = TB-4" — is technically incorrect. Full-length TB-4 has been studied in several disease indications (Sigma-Tau / RegeneRx Biopharmaceuticals ran clinical trials in dry eye disease and dermal repair); the synthetic TB-500 fragment sold through recovery-peptide channels has a much thinner clinical-trial footprint.
The 2026 American Journal of Sports Medicine primer for orthopaedic and sports medicine physicians covers the broader injectable peptide landscape including TB-500 and is the cleanest single overview [7]. The 2026 JAAOS Global Research Reviews paper similarly surveys orthopaedic applications [8]. The 2026 Sports Medicine (Auckland) review on approved and unapproved peptide therapies is the most thorough critical assessment of the category [9].
Across these reviews, the consistent conclusion: animal-model data is suggestive, the proposed mechanism (anti-inflammatory, pro-angiogenic, actin-binding promoting cellular migration) is biologically plausible, and the human-trial evidence does not yet support routine clinical recommendation. TB-500 is best understood as a research compound that has migrated into commercial use ahead of the data.
Both BPC-157 and TB-500 are prohibited at all times under the WADA Prohibited List [11], in the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This applies to in-competition and out-of-competition testing alike. An athlete subject to WADA testing — which includes NCAA student-athletes through the WADA-aligned USADA framework, Olympic-pathway athletes, professional athletes in WADA-aligned sports — risks a sanction for use of either compound regardless of medical justification.
The 2026 Sports Medicine review and the 2026 Journal of Sports Medicine and Physical Fitness critical review document the broader pattern of unapproved peptide use in recreational and professional sport [9]. The pattern is well-characterized in the anti-doping literature even though the underlying compounds are not FDA-approved drugs.
Three things a reader considering recovery peptides should keep front of mind.
The preclinical-to-clinical gap is real and large. Animal models of tendon repair and wound healing have been historically poor predictors of human clinical outcomes. The preclinical BPC-157 literature is genuinely interesting; the inference that "it worked in rats, therefore it works in my patellar tendinopathy" is not supported by the trial data that would actually establish that.
Source quality is the practical risk. BPC-157 and TB-500 sold through research-chemical suppliers and gray-market channels are not subject to USP standards, third-party potency verification, or sterility testing comparable to compounding-pharmacy operations. Counterfeit and underdosed products are well-documented in the broader unapproved-peptide market. Even within the legitimate 503A compounding pathway, the FDA's Category 2 placement of BPC-157 means high-volume compounding of it is operating at the edge of the regulatory envelope.
Athlete exposure is real. A patient subject to anti-doping testing should not use these compounds for any indication, regardless of how the supplying provider frames the regulatory status.
The animal data is suggestive. The 2025 HSS systematic review concludes that the human evidence base does not yet support routine clinical use [3]. The single most-cited human study was small, open-label, and in a low-impact journal [6]. We would not promise a tendon-healing outcome on the strength of the current literature.
Yes, by the WADA Prohibited List S2 category, at all times [11]. NCAA, Olympic-pathway, and most professional athletes in WADA-aligned sports are subject to this.
TB-500 is a synthetic fragment of the full Thymosin Beta-4 protein. They share part of the sequence but are not the same molecule. Marketing copy that treats them as interchangeable is imprecise.
The safety profile in case-series and animal data is generally favorable, but a definitive answer requires randomized human-trial data that does not yet exist. The 2025 "Regeneration or Risk?" review is the most balanced summary [5].
Some platforms in our provider review set carry BPC-157 or related recovery peptides as part of broader menus — TeleZenMD is the broadest example. Where a provider offers these compounds, the questions to ask are the same as for any compounded peptide: compounding pharmacy identity, regulatory pathway used, and the prescribing rationale for an off-label, non-FDA-approved use.
Editorial note: Informational only — not medical advice. Decisions about recovery peptide use should be made with a clinician familiar with the literature and with the patient's anti-doping testing exposure. Last reviewed June 2026.